Please see supplemental Table 4 in the supplemental Appendix for more detail of the hemostatic efficacy and safety of operative procedures, including a description of the dose and timing of perioperative hemostatic treatment.

aPCC, activated prothrombin complex concentrate; CRP, C-reactive protein; HA, hemophilia A; HB, hemophilia B; LDH, lactate dehydrogenase; rFVIIa, activated recombinant FVII.

The hemostatic efficacy rating of the procedure was assessed by the respective investigators.

Although the hemostatic efficacy rating was not reported for these procedures, it was noted by the investigator that each of these procedures were covered by fitusiran alone with the perioperative hemostatic plan using only reduced doses and frequency of aPCC as recommended in the bleed management dosing guidelines in the protocol. None of these procedures required AT reversal, and no excessive bleed occurred during surgeries. Thus, it was concluded that fitusiran in association with reduced dose and frequency of aPCC administered perioperatively demonstrated successful hemostatic management.

The procedure was covered by fitusiran alone without using any FVIII concentrate dose perioperatively. The procedure did not require AT reversal, and no excessive bleed occurred during the surgery. Fitusiran has demonstrated successful hemostatic management without any adjunction of FVIII concentrate perioperatively.